70121-1755Level 3
ALYMSYS (bevacizumab-maly)
**Product type:** Human Prescription Drug
**Active ingredient:** BEVACIZUMAB
**Strength:** 400 mg/16mL
**Dosage form:** Injection, Solution
**Route:** Intravenous
**Labeler:** Amneal Pharmaceuticals LLC
**Marketing category:** BLA (BLA761231)
**Pharmacologic class:** Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
GET
/api/v1/systems/ndc_fda/nodes/70121-1755Hierarchy Explorer
Loading...
Cross-system equivalences0
No cross-system equivalences mapped for this node.